公开(公告)号：US20250066366A1

公开(公告)日：2025-02-27

申请号：US18707572

申请日：2022-11-04

Applicant: Shenzhen AntiV Pharma Co., Ltd.

Inventor： Xumu ZHANG ,  Yingjun LI ,  Qifan ZHOU ,  Guanguan LI

IPC: C07D487/04 ,  A61K31/53

Abstract: Provided herein are a crystal form of an isobutyrate nucleoside compound, and a preparation method. The crystal form is III; the X-ray powder diffraction pattern thereof has characteristic peaks at diffraction angles, 2θ, 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2° and 28.66±0.2°. The crystal form III has good physical and chemical stability. The preparation method for the crystal form is simple to operate and high in repeatability.

公开(公告)号：US20250066365A1

公开(公告)日：2025-02-27

申请号：US18694747

申请日：2022-09-23

Applicant: Katholieke Universiteit Leuven

Inventor： Piet Herdewijn ,  Zihua Zheng ,  Elisabetta Groaz

IPC: C07D487/04 ,  A61K31/53 ,  B01J31/22 ,  B01J31/24

Abstract: The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.

公开(公告)号：US12234241B2

公开(公告)日：2025-02-25

申请号：US18634599

申请日：2024-04-12

Applicant: Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.

Inventor： Zhengwu Shen ,  Bin Deng ,  Yunxiang Fan ,  Yangli Shen ,  Xuejiang Chen ,  Yinshuang Wu ,  Xinyi Wang ,  Hongzhu Bian

IPC: C07D487/04 ,  A61K31/53 ,  A61P35/00

Abstract: Provided is an imidazotriazine thiobenzamide derivative of formula (I), A preparation method for the imidazotriazine thiobenzamide derivative, and a use of the imidazotriazine thiobenzamide derivative or an isomer, a pharmaceutically-acceptable salt, or a prodrug thereof in the preparation of drugs for the treatment of cancer are also provided.

公开(公告)号：US12233070B2

公开(公告)日：2025-02-25

申请号：US17361754

申请日：2021-06-29

Applicant: University of Mississippi Medical Center

Inventor： James K. Rowlett

IPC: A61P25/30 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/53

Abstract: Disclosed are compositions and methods for treating benzodiazepine misuse and/or use disorder. A method of treating benzodiazepine misuse and/or use disorder includes administering to a subject in need thereof of an effective amount of a compound provides both partial modulator and antagonist effects at GABAA receptors.

公开(公告)号：US12233059B2

公开(公告)日：2025-02-25

申请号：US18670637

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit Etkin ,  Wei Wu ,  Chao Wang ,  Nicholas Cooper ,  Joshua Jordan ,  Adam Savitz

IPC: A61K31/496 ,  A61K9/00 ,  A61K31/19 ,  A61K31/53 ,  A61K33/00 ,  A61P25/24 ,  A61B5/16 ,  A61B5/374

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US12226405B2

公开(公告)日：2025-02-18

申请号：US17241981

申请日：2021-04-27

Applicant: Novartis AG

Inventor： Robin Alec Fairhurst ,  Christine Fritsch ,  Marc Gerspacher ,  Jürgen Hans-Hermann Hinrichs ,  Jean-Baptiste Georges Armand Langlois ,  Catherine Leblanc ,  Tengfei Li ,  Edwige Liliane Jeanne Lorthiois ,  Christophe Mura ,  Cristina Montserrat Nieto-Oberhuber ,  Milen Todorov ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: A61K31/437 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4747 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/635 ,  A61K31/675 ,  A61P35/00 ,  C07D471/10 ,  C07D471/20 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D495/22

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

公开(公告)号：US20250049881A1

公开(公告)日：2025-02-13

申请号：US18602930

申请日：2024-03-12

Applicant: Bausch Health Ireland Limited

Inventor： Stephen Comiskey ,  Rong Feng ,  John Foss ,  Kunwar Shailubhai

IPC: A61K38/10 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/192 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/765 ,  A61K31/78 ,  A61K38/12 ,  A61K45/06 ,  A61K47/12 ,  A61K47/38 ,  C07K7/08 ,  C07K7/54 ,  C07K7/64

Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

公开(公告)号：US20250032496A1

公开(公告)日：2025-01-30

申请号：US18795777

申请日：2024-08-06

Applicant: Enalare Therapeutics Inc.

Inventor： Joseph Pergolizzi ,  Thomas Miller ,  Alfred Schweikert

IPC: A61K31/519 ,  A61K31/53 ,  A61P11/00

Abstract: Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.

公开(公告)号：US12209071B2

公开(公告)日：2025-01-28

申请号：US17830724

申请日：2022-06-02

Applicant: AlzeCure Pharma AB

Inventor： Gunnar Nordvall ,  Pontus Forsell

IPC: A61K31/53 ,  C07D251/30 ,  C07D401/04 ,  C07D403/10 ,  C07D405/12 ,  C07D409/04 ,  C07D413/10 ,  C07D417/04

Abstract: There is provided herein a compound of formula I, wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

公开(公告)号：US20250025468A1

公开(公告)日：2025-01-23

申请号：US18906967

申请日：2024-10-04

Applicant: ARIBIO CO., LTD. ,  SK CHEMICALS CO., LTD.

Inventor： Jai Jun Choung ,  Yoon Pyo Choi ,  Byungwoo Kang ,  Fred Kim ,  Mi Sun Choung

IPC: A61K31/519 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/522 ,  A61K31/53 ,  A61P25/28

Abstract: The present invention provides methods for reducing amyloid beta formation and for treating diseases associated with the accumulation of amyloid beta. The present invention provides (1) A β aggregation inhibition by A β Oligomer/Fibril formation inhibition, (2) BACE-1 reduction through β-Amyloidogenic Processing inhibition, (3) increased cerebral blood flow, (4) activation of Neuronal cell Death inhibition and Neurogenesis, Synaptogenesis, Angiogenesis promotion, (5) DKK-1 inhibition by Wnt Signaling and Aβ production Positive Feedback Loop for inhibition of APP to suppress Aβ accumulation, (6) Autophagy activation by cells, by providing Mirodenafil, Sildenafil, Vardenafil, Tadalafil, Udenafil, Dasantafil, and Avanafil and a Pharmaceutically Acceptable Salt, Solvate, and Hydrate in selected compounds key of ingredient containing drug compound composition, and this with the treatment method provided.